

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Ozenoxacin. [Updated 2019 May 1]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Ozenoxacin

Revised: May 1, 2019.

CASRN: 245765-41-7

Drug Levels and Effects

Summary of Use during Lactation

No information is available on ozenoxacin cream during breastfeeding. Because ozenoxacin is poorly absorbed after topical application, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants after maternal application away from the breast. Although quinolones are generally acceptable for systemic use, ozenoxacin should be avoided on the nipple because the infant could ingest the drug via licking.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Mupirocin

Substance Identification

Substance Name

Ozenoxacin

CAS Registry Number

245765-41-7

Drug Class

Breast Feeding

Lactation

Quinolones

Anti-Infective Agents, Local

Anti-Bacterial Agents